Stockscreener 앱 받기
2.50
1.21%
0.03
시간 외 거래:
2.56
0.06
+2.40%
전일 마감가:
$2.47
열려 있는:
$2.47
하루 거래량:
2.53M
Relative Volume:
0.35
시가총액:
$692.66M
수익:
-
순이익/손실:
$-225.14M
주가수익비율:
-1.2755
EPS:
-1.96
순현금흐름:
$-192.27M
1주 성능:
-7.06%
1개월 성능:
+15.74%
6개월 성능:
+245.78%
1년 성능:
+420.83%
1일 변동 폭
$2.4001
$2.52
1주일 범위
$2.37
$2.68
52주 변동 폭
$0.3546
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
명칭
Invivyd Inc
전화
(781) 819-0080
주소
209 CHURCH STREET, NEW HAVEN
IVVD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
2.50 | 684.35M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-22 | 개시 | BTIG Research | Buy |
| 2025-11-25 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-10-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-26 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 개시 | H.C. Wainwright | Buy |
모두보기
Invivyd Inc 주식(IVVD)의 최신 뉴스
Invivyd Inc. | Latest News & Innovations - shababeek.org
BTIG initiates Invivyd (IVVD) coverage, cites VYD2311’s superior market potential over Pemgarda - MSN
BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311’s Superior Market Potential Over Pemgarda - Insider Monkey
Invivyd (NASDAQ:IVVD) Trading Down 3.7%Here's Why - MarketBeat
Is Invivyd Inc. stock supported by strong fundamentalsChart Pattern Recognition & Minimal Risk High Reward - bollywoodhelpline.com
Does Invivyd’s (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? - Yahoo Finance
BTIG Reiterates Invivyd (IVVD) Buy Recommendation - Nasdaq
BTIG Research Upgrades Invivyd (NASDAQ:IVVD) to Strong-Buy - MarketBeat
Invivyd granted FDA fast track status for COVID therapy - MSN
FDA grants fast track designation for Invivyd’s COVID antibody By Investing.com - Investing.com Nigeria
Invivyd begins phase 3 trial of COVID prevention antibody VYD2311 By Investing.com - Investing.com Nigeria
US OPEN: Markets wobble amid low volumes and resilient GDP (23.12.2025) - XTB.com
Is Invivyd’s (IVVD) Index Debut Quietly Reframing Its Long-Term Biotech Positioning? - simplywall.st
Invivyd wins FDA fast track tag for COVID drug (IVVD:NASDAQ) - Seeking Alpha
Invivyd Says Vaccine-Alternative Antibody to Prevent COVID Gets FDA Fast Track Designation; Phase 3 Trial Launched - marketscreener.com
Invivyd’s COVID Antibody VYD2311 Receives FDA Fast Track - TipRanks
FDA grants fast track designation for Invivyd’s COVID antibody - Investing.com India
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - The Manila Times
Invivyd announces initiation of DECLARATION clinical trial, a phase 3 placebo-controlled pivotal study of VYD2311, a vaccine-alternative antibody to prevent Covid-19 - marketscreener.com
Invivyd stock rises after FDA grants Fast Track designation for COVID antibody - Investing.com Canada
Invivyd, Inc. Earns Fast Track Designation for COVID Antibody - TradingView — Track All Markets
Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody - TradingView — Track All Markets
Invivyd begins phase 3 trial of COVID prevention antibody VYD2311 - Investing.com
FDA puts COVID prevention shot alternative from Invivyd on Fast Track - Stock Titan
New antibody shot aims to offer vaccine-alternative protection from COVID - Stock Titan
Invivyd (IVVD): Assessing Valuation After S&P Biotechnology Select Industry Index Inclusion - Yahoo Finance
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
Invivyd announces proposed public offering of common stock - MSN
Invivyd, Inc. (IVVD): Advancing RSV antibody VBY329 amid analyst downgrade - MSN
Invivyd (NASDAQ:IVVD) Shares Gap UpShould You Buy? - MarketBeat
BTIG Initiates Invivyd at Buy With $10 Price Target - marketscreener.com
Invivyd stock initiated with Buy rating at BTIG on COVID antibody potential - Investing.com India
Invivyd stock initiated with Buy rating at BTIG on COVID antibody potential By Investing.com - Investing.com South Africa
BTIG Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - Nasdaq
Invivyd, Inc.(NasdaqGM: IVVD) added to S&P Biotechnology Select Industry Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to NASDAQ Biotechnology Index - marketscreener.com
Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Invivyd Inc (IVVD) Stock News & Articles - 24/7 Wall St.
Aug Sentiment: Is Invivyd Inc. stock undervalued vs historical averagesWeekly Investment Summary & Smart Swing Trading Alerts - Улправда
How Invivyd Inc. stock reacts to Fed rate cutsProduct Launch & Technical Pattern Alert System - ulpravda.ru
Is Invivyd Inc. stock a good choice for value investorsJuly 2025 Gainers & Long Hold Capital Preservation Plans - Улправда
Is Invivyd Inc. stock undervalued vs historical averages2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
How analysts rate Invivyd Inc. stock todayWeekly Stock Report & High Accuracy Investment Signals - DonanımHaber
How Recent Clinical Progress Is Rewriting the Story for Invivyd - Yahoo Finance
What sentiment indicators say about Invivyd Inc. stock2025 Sector Review & Smart Money Movement Tracker - Улправда
Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade - Yahoo Finance
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
Invivyd Nominates RSV Antibody, Spurs Market Interest - StocksToTrade
Invivyd (NASDAQ:IVVD) Stock Price Up 6.1%Still a Buy? - MarketBeat
Invivyd Inc (IVVD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):